Two Sigma Investments LP lifted its holdings in Incyte Co. (NASDAQ:INCY) by 143.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 729,107 shares of the biopharmaceutical company’s stock after buying an additional 429,181 shares during the period. Two Sigma Investments LP owned about 0.35% of Incyte worth $69,054,000 at the end of the most recent reporting period.
Several other institutional investors have also bought and sold shares of the company. Sands Capital Management LLC lifted its position in shares of Incyte by 8.2% in the 4th quarter. Sands Capital Management LLC now owns 8,191,287 shares of the biopharmaceutical company’s stock worth $775,797,000 after purchasing an additional 621,323 shares during the period. Capital International Investors grew its position in Incyte by 1.4% during the third quarter. Capital International Investors now owns 6,494,566 shares of the biopharmaceutical company’s stock valued at $758,176,000 after buying an additional 87,369 shares during the period. Geode Capital Management LLC grew its position in Incyte by 5.8% during the fourth quarter. Geode Capital Management LLC now owns 1,938,238 shares of the biopharmaceutical company’s stock valued at $183,205,000 after buying an additional 105,692 shares during the period. Bank of New York Mellon Corp grew its position in Incyte by 0.4% during the fourth quarter. Bank of New York Mellon Corp now owns 1,682,019 shares of the biopharmaceutical company’s stock valued at $159,304,000 after buying an additional 7,463 shares during the period. Finally, HealthCor Management L.P. grew its position in Incyte by 125.5% during the fourth quarter. HealthCor Management L.P. now owns 1,350,000 shares of the biopharmaceutical company’s stock valued at $127,859,000 after buying an additional 751,450 shares during the period. Hedge funds and other institutional investors own 93.58% of the company’s stock.
In related news, EVP Vijay K. Iyengar sold 5,000 shares of the firm’s stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $97.26, for a total transaction of $486,300.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David W. Gryska sold 6,760 shares of the firm’s stock in a transaction dated Friday, January 5th. The stock was sold at an average price of $98.87, for a total transaction of $668,361.20. Following the sale, the insider now owns 20,752 shares of the company’s stock, valued at $2,051,750.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 15,670 shares of company stock valued at $1,489,181. 17.70% of the stock is owned by company insiders.
Several analysts recently commented on INCY shares. Royal Bank of Canada dropped their price target on shares of Incyte from $136.00 to $120.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 21st. Nomura reaffirmed a “buy” rating on shares of Incyte in a report on Thursday, February 1st. Raymond James Financial set a $159.00 price objective on shares of Incyte and gave the company a “buy” rating in a report on Wednesday, February 28th. Deutsche Bank initiated coverage on shares of Incyte in a report on Tuesday, December 12th. They set a “hold” rating and a $106.00 price objective on the stock. Finally, Credit Suisse Group set a $145.00 price objective on shares of Incyte and gave the company a “buy” rating in a report on Wednesday, February 14th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $142.83.
Incyte Co. (INCY) traded up $0.23 during trading on Tuesday, reaching $94.68. 128,107 shares of the company traded hands, compared to its average volume of 1,717,484. Incyte Co. has a 52-week low of $80.85 and a 52-week high of $153.15. The firm has a market capitalization of $19,930.00, a PE ratio of -60.54 and a beta of 0.64. The company has a current ratio of 4.01, a quick ratio of 3.99 and a debt-to-equity ratio of 0.01.
Incyte (NASDAQ:INCY) last released its quarterly earnings data on Thursday, February 15th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.52) by $0.54. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The firm had revenue of $444.20 million during the quarter, compared to analysts’ expectations of $435.23 million. During the same period last year, the business earned $0.05 earnings per share. Incyte’s revenue was up 36.0% compared to the same quarter last year. research analysts anticipate that Incyte Co. will post -0.28 earnings per share for the current fiscal year.
Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).
Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Co. (NASDAQ:INCY).
Receive News & Ratings for Incyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte and related companies with MarketBeat.com's FREE daily email newsletter.